Checkmate 205: Nivolumab (nivo) in classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and brentuximab vedotin (BV)--A phase 2 study.
暂无分享，去创建一个
K. Savage | M. Shipp | A. Santoro | S. Ansell | P. Zinzani | S. Rodig | P. Armand | A. Younes | J. Kuruvilla | J. Timmerman | M. Trněný | S. Parker | A. Engert | M. Fanale | V. Ratanatharathorn | G. Collins | Kazunobu Kato | B. Farsaci | J. Cohen